Harnessing Muscle–Liver Crosstalk to Treat Nonalcoholic Steatohepatitis
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) has reached epidemic proportions, affecting an estimated one-quarter of the world’s adult population. Multiple organ systems have been implicated in the pathophysiology of NAFLD; however, the role of skeletal muscle has until recently been largely overlooked. A growing body of evidence places skeletal muscle—via its impact on insulin resistance and systemic inflammation—and the muscle-liver axis at the center of the NAFLD pathogenic cascade. Population-based studies suggest that sarcopenia is an effect-modifier across the NAFLD spectrum in that it is tightly linked to an increased risk of non-alcoholic fatty liver, non-alcoholic steatohepatitis (NASH), and advanced liver fibrosis, all independent of obesity and insulin resistance. Longitudinal studies suggest that increases in skeletal muscle mass over time may both reduce the incidence of NAFLD and improve preexisting NAFLD. Adverse muscle composition, comprising both low muscle volume and high muscle fat infiltration (myosteatosis), is highly prevalent in patients with NAFLD. The risk of functional disability conferred by low muscle volume in NAFLD is further exacerbated by the presence of myosteatosis, which is twice as common in NAFLD as in other chronic liver diseases. Crosstalk between muscle and liver is influenced by several factors, including obesity, physical inactivity, ectopic fat deposition, oxidative stress, and proinflammatory mediators. In this perspective review, we discuss key pathophysiological processes driving sarcopenia in NAFLD: anabolic resistance, insulin resistance, metabolic inflexibility and systemic inflammation. Interventions that modify muscle quantity (mass), muscle quality (fat), and physical function by simultaneously engaging multiple targets and pathways implicated in muscle-liver crosstalk may be required to address the multifactorial pathogenesis of NAFLD/NASH and provide effective and durable therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818
Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001779 · Cited by 12,728
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · cited 1×
“3% among individuals with T2D (13), contributes to increasing rates of cirrhosis (14, 15), and is rapidly emerging as the leading cause of liver transplantation (16, 17).”
BackgroundA PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis
Boström, P., Wu, J., Jedrychowski, M. P., Korde, A., Ye, L., Lo, J. C., Rasbach, K. A., Boström, E. A., Choi, J. H., Long, J. Z., et al. (2012) · Nature · doi:10.1038/nature10777 · Cited by 4,810
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afz046 · Cited by 3,803
Janssen, I., Heymsfield, S. B., & Ross, R. (2002) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2002.50216.x · Cited by 3,139
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548
Studenski, S. A., Peters, K. W., Alley, D. E., Cawthon, P. M., McLean, R. R., Harris, T. B., Ferrucci, L., Guralnik, J. M., Fragala, M. S., Kenny, A. M., et al. (2014) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glu010 · Cited by 2,545
Younossi, Z. M., Golabi, P., de Avila, L., Paik, J. M., Srishord, M., Fukui, N., Qiu, Y., Burns, L., Afendy, A., & Nader, F. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.021 · Cited by 2,235 · cited 6×
“Interestingly, NAFLD participants presenting with normal muscle composition had similar backgroundmetabolic and functional risk as the control (low liver fat and alcohol consumption) population (Figure 3),with the exception of a higher T2D prevalence (69).”
BackgroundInfluentialSkeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes
DeFronzo, R. A., & Tripathy, D. (2009) · Diabetes Care · doi:10.2337/dc09-s302 · Cited by 2,102 · cited 1×
“Yet, few if any of these pathways explicitly involve skeletal muscle, the principal organ responsible for glucose disposal (6) and energy homeostasis (7), key processes that can impact the core pathogenesis of a systemic metabolic disease such as NAFLD (8).”
BackgroundSepanlou, S. G., Safiri, S., Bisignano, C., Ikuta, K. S., Merat, S., Saberifiroozi, M., Poustchi, H., Tsoi, D., Colombara, D. V., Abdoli, A., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30349-8 · Cited by 1,714
Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies
Batsis, J. A., & Villareal, D. T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0062-9 · Cited by 1,382
Chitturi, S., Abeygunasekera, S., Farrell, G. C., Holmes-Walker, J., Hui, J. M., Fung, C., Karim, R., Lin, R., Samarasinghe, D., Liddle, C., et al. (2002) · Hepatology · doi:10.1053/jhep.2002.30692 · Cited by 1,122
Kelley, D. E., Goodpaster, B., Wing, R. R., & Simoneau, J.-A. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.277.6.e1130 · Cited by 1,096
Hormone-fuel interrelationships during fasting.
Cahill, G. F., Herrera, M. G., Morgan, A. P., Soeldner, J. S., Steinke, J., Levy, P. L., Reichard, G. A., & Kipnis, D. M. (1966) · Journal of Clinical Investigation · doi:10.1172/jci105481 · Cited by 1,036 · cited 1×
“This results in a steady supply of FAs to be used as the major fuel source during fasting (110).”
BackgroundSkeletal muscle metabolism is a major determinant of resting energy expenditure.
Zurlo, F., Larson, K., Bogardus, C., & Ravussin, E. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114857 · Cited by 959 · cited 2×
“Yet, few if any of these pathways explicitly involve skeletal muscle, the principal organ responsible for glucose disposal (6) and energy homeostasis (7), key processes that can impact the core pathogenesis of a systemic metabolic disease such as NAFLD (8).”
BackgroundMoreno-Navarrete, J. M., Ortega, F., Serrano, M., Guerra, E., Pardo, G., Tinahones, F., Ricart, W., & Fernández-Real, J. M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2749 · Cited by 788 · cited 1×
“Irisin expression in skeletal muscle is reduced in obesity and is related to insulin sensitivity (143).”
BackgroundZisman, A., Peroni, O. D., Abel, E. D., Michael, M. D., Mauvais-Jarvis, F., Lowell, B. B., Wojtaszewski, J. F. P., Hirshman, M. F., Virkamaki, A., Goodyear, L. J., et al. (2000) · Nature Medicine · doi:10.1038/78693 · Cited by 743 · cited 1×
“Animal models with muscle-specific glucose transporter 4 knockouts develop severe insulin resistance (90).”
BackgroundZhang, Y., Li, R., Meng, Y., Li, S., Donelan, W., Zhao, Y., Qi, L., Zhang, M., Wang, X., Cui, T., et al. (2014) · Diabetes · doi:10.2337/db13-1106 · Cited by 733
Intermuscular fat: a review of the consequences and causes
Addison, O., Marcus, R. L., LaStayo, P. C., & Ryan, A. S. (2014) · International Journal of Endocrinology · doi:10.1155/2014/309570 · Cited by 656 · cited 1×
“Myosteatosis has been linked to metabolic, functional, and clinical outcomes (65), a higher risk for cirrhosis-related complications such as hepatic encephalopathy (66), and overall mortality in patients with cirrhosis (67).”
BackgroundOxidative capacity and ageing in human muscle
Conley, K. E., Jubrias, S. A., & Esselman, P. C. (2000) · The Journal of Physiology · doi:10.1111/j.1469-7793.2000.t01-1-00203.x · Cited by 651 · cited 1×
“Thus, loss of muscle mass can lead to significant whole-body metabolic disturbances that include decline in basal metabolic rate, and loss of mitochondrial volume, density, and oxidative capacity, with further exacerbation of muscle loss (Figure 4) (104, 105).”
BackgroundInsulin resistance and sarcopenia: mechanistic links between common co-morbidities
Cleasby, M. E., Jamieson, P. M., & Atherton, P. J. (2016) · Journal of Endocrinology · doi:10.1530/joe-15-0533 · Cited by 596
The macrophage switch in obesity development
Castoldi, A., Naffah de Souza, C., Câmara, N. O. S., & Moraes-Vieira, P. M. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00637 · Cited by 575
Metabolic flexibility and insulin resistance
Galgani, J. E., Moro, C., & Ravussin, E. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90558.2008 · Cited by 532 · cited 2×
“, FAs during fasting and carbohydrate in fed states) for energy generation is referred to as metabolic flexibility (109).”
BackgroundSayiner, M., Koenig, A., Henry, L., & Younossi, Z. M. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.10.001 · Cited by 529
Montano-Loza, A. J., Angulo, P., Meza-Junco, J., Prado, C. M. M., Sawyer, M. B., Beaumont, C., Esfandiari, N., Ma, M., & Baracos, V. E. (2016) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12039 · Cited by 512 · cited 1×
“Myosteatosis has been linked to metabolic, functional, and clinical outcomes (65), a higher risk for cirrhosis-related complications such as hepatic encephalopathy (66), and overall mortality in patients with cirrhosis (67).”
BackgroundHeymsfield, S. B., Gonzalez, M. C., Lu, J., Jia, G., & Zheng, J. (2015) · Proceedings of the Nutrition Society · doi:10.1017/s0029665115000129 · Cited by 483
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis
Koo, B. K., Kim, D., Joo, S. K., Kim, J. H., Chang, M. S., Kim, B. G., Lee, K. L., & Kim, W. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.08.019 · Cited by 440 · cited 4×
“There was also a strong graded response with disease severity for NASH and fibrosis stage, both independent of obesity (52, 55).”
BackgroundMethodInfluentialGuo, T., Jou, W., Chanturiya, T., Portas, J., Gavrilova, O., & McPherron, A. C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004937 · Cited by 402 · cited 1×
“Deletion of myostatin in mouse models produces dramatic improvements in insulin sensitivity and glucose uptake, and a reduction in adiposity (134).”
BackgroundMarra, M., Sammarco, R., De Lorenzo, A., Iellamo, F., Siervo, M., Pietrobelli, A., Donini, L. M., Santarpia, L., Cataldi, M., Pasanisi, F., et al. (2019) · Contrast Media & Molecular Imaging · doi:10.1155/2019/3548284 · Cited by 401
Myostatin and the skeletal muscle atrophy and hypertrophy signaling pathways
Rodriguez, J., Vernus, B., Chelh, I., Cassar-Malek, I., Gabillard, J. C., Hadj Sassi, A., Seiliez, I., Picard, B., & Bonnieu, A. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1689-x · Cited by 397 · cited 1×
“Myostatin Myostatin is a well-establishedmyokine that plays a central role in inhibiting skeletal muscle growth andmass (130).”
BackgroundHong, H. C., Hwang, S. Y., Choi, H. Y., Yoo, H. J., Seo, J. A., Kim, S. G., Kim, N. H., Baik, S. H., Choi, D. S., & Choi, K. M. (2014) · Hepatology · doi:10.1002/hep.26716 · Cited by 385
Tournadre, A., Vial, G., Capel, F., Soubrier, M., & Boirie, Y. (2019) · Joint Bone Spine · doi:10.1016/j.jbspin.2018.08.001 · Cited by 375
Lazo, M., Solga, S. F., Horska, A., Bonekamp, S., Diehl, A. M., Brancati, F. L., Wagenknecht, L. E., Pi-Sunyer, F. X., Kahn, S. E., Clark, J. M., et al. (2010) · Diabetes Care · doi:10.2337/dc10-0856 · Cited by 367
Bacchi, E., Negri, C., Targher, G., Faccioli, N., Lanza, M., Zoppini, G., Zanolin, E., Schena, F., Bonora, E., & Moghetti, P. (2013) · Hepatology · doi:10.1002/hep.26393 · Cited by 350 · cited 1×
“org 8 shown to significantly reduce intrahepatic fat content independent of weight loss in subjects with fatty liver and type 2 diabetes (106, 107).”
BackgroundAchamrah, N., Colange, G., Delay, J., Rimbert, A., Folope, V., Petit, A., Grigioni, S., Déchelotte, P., & Coëffier, M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200465 · Cited by 337
Huh, J. Y., Dincer, F., Mesfum, E., & Mantzoros, C. S. (2014) · International Journal of Obesity · doi:10.1038/ijo.2014.42 · Cited by 309
Health Consequences of Sarcopenic Obesity: A Narrative Review
Roh, E., & Choi, K. M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00332 · Cited by 304
Fujita, S., Rasmussen, B. B., Cadenas, J. G., Drummond, M. J., Glynn, E. L., Sattler, F. R., & Volpi, E. (2007) · Diabetes · doi:10.2337/db06-1566 · Cited by 224 · cited 1×
“Insulin, via its activation of p38 mitogenactivated protein kinase (MAPK) and mTOR, stimulates mRNA translation of genes responsible for muscle proliferation and hypertrophy (94).”
BackgroundWilkes, E. A., Selby, A. L., Atherton, P. J., Patel, R., Rankin, D., Smith, K., & Rennie, M. J. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.27543 · Cited by 204
Kim, G., Lee, S., Lee, Y., Jun, J. E., Ahn, J., Bae, J. C., Jin, S., Hur, K. Y., Jee, J. H., Lee, M., et al. (2018) · Hepatology · doi:10.1002/hep.30049 · Cited by 198 · cited 5×
“Recent evidence in the context of NAFLD and NASH, such as that from Kim et al (49). offers compelling associations between changes in skeletal muscle index (SMI) and both NAFLD incidence and resolution of existing NAFLD.”
BackgroundInfluentialZhang, C., McFarlane, C., Lokireddy, S., Masuda, S., Ge, X., Gluckman, P. D., Sharma, M., & Kambadur, R. (2012) · Diabetologia · doi:10.1007/s00125-011-2304-4 · Cited by 192 · cited 1×
“Inactivation or absence of functional myostatin increased lipolysis and FA oxidation in peripheral tissues, increased muscle mass (135, 136), and ameliorated fatty liver in mice (137).”
BackgroundSarcopenia in the elderly: basic and clinical issues
Wang, C., & Bai, L. (2012) · Geriatrics & Gerontology International · doi:10.1111/j.1447-0594.2012.00851.x · Cited by 170
Effects of Obesity on Substrate Utilization during Exercise
Goodpaster, B. H., Wolfe, R. R., & Kelley, D. E. (2002) · Obesity Research · doi:10.1038/oby.2002.78 · Cited by 169
The ageing neuromuscular system and sarcopenia: A mitochondrial perspective
Rygiel, K. A., Picard, M., & Turnbull, D. M. (2016) · The Journal of Physiology · doi:10.1113/jp271212 · Cited by 165 · cited 1×
“Thus, loss of muscle mass can lead to significant whole-body metabolic disturbances that include decline in basal metabolic rate, and loss of mitochondrial volume, density, and oxidative capacity, with further exacerbation of muscle loss (Figure 4) (104, 105).”
BackgroundFujita, S., Glynn, E. L., Timmerman, K. L., Rasmussen, B. B., & Volpi, E. (2009) · Diabetologia · doi:10.1007/s00125-009-1430-8 · Cited by 164
Zhang, C., McFarlane, C., Lokireddy, S., Bonala, S., Ge, X., Masuda, S., Gluckman, P. D., Sharma, M., & Kambadur, R. (2011) · Diabetologia · doi:10.1007/s00125-011-2079-7 · Cited by 158 · cited 1×
“Inactivation or absence of functional myostatin increased lipolysis and FA oxidation in peripheral tissues, increased muscle mass (135, 136), and ameliorated fatty liver in mice (137).”
BackgroundSarcopenic obesity: molecular clues to a better understanding of its pathogenesis?
Kob, R., Bollheimer, L. C., Bertsch, T., Fellner, C., Djukic, M., Sieber, C. C., & Fischer, B. E. (2015) · Biogerontology · doi:10.1007/s10522-014-9539-7 · Cited by 151 · cited 1×
“These cytokines negatively impact skeletal muscle by upregulating proteasomal decay of filament proteins and promoting apoptosis (123).”
BackgroundCharacterization of the metabolic effects of irisin on skeletal muscle in vitro
Vaughan, R. A., Gannon, N. P., Barberena, M. A., Garcia‐Smith, R., Bisoffi, M., Mermier, C. M., Conn, C. A., & Trujillo, K. A. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12268 · Cited by 150
Farmer, R. E., Mathur, R., Schmidt, A. F., Bhaskaran, K., Fatemifar, G., Eastwood, S. V., Finan, C., Denaxas, S., Smeeth, L., & Chaturvedi, N. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011638 · Cited by 144
Devries, M. C., McGlory, C., Bolster, D. R., Kamil, A., Rahn, M., Harkness, L., Baker, S. K., & Phillips, S. M. (2018) · The Journal of Nutrition · doi:10.1093/jn/nxy091 · Cited by 141 · cited 5×
“Protein synthesis in skeletal muscle is activated by anabolic factors such as amino acids (AAs), hormones (insulin, growth hormone, and insulin-like growth factor 1), and mechanical stimulus (muscle contraction) (82).”
BackgroundInfluentialIs interleukin-1β a culprit in macrophage-adipocyte crosstalk in obesity?
Bing, C. (2015) · Adipocyte · doi:10.4161/21623945.2014.979661 · Cited by 127
Cai, C., Song, X., Chen, Y., Chen, X., & Yu, C. (2020) · Hepatology International · doi:10.1007/s12072-019-09964-1 · Cited by 118
Skeletal muscle protein balance and metabolism in the elderly
S. Fry, C., & B. Rasmussen, B. (2011) · Current Aging Sciencee · doi:10.2174/1874609811104030260 · Cited by 111 · cited 1×
“Key Mechanisms Anabolic Resistance Dysregulated nitrogen homeostasis underpins impaired hepatic metabolism (80), whereby an imbalance between muscle protein synthesis and muscle protein breakdown ultimately contributes to the decreased muscle mass that accompanies liver disease (81).”
BackgroundOn the Definition of Sarcopenia in the Presence of Aging and Obesity—Initial Results from UK Biobank
Linge, J., Heymsfield, S. B., & Dahlqvist Leinhard, O. (2020) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glz229 · Cited by 103
Linge, J., Ekstedt, M., & Dahlqvist Leinhard, O. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2020.100197 · Cited by 98 · cited 4×
“0% of the participants with NAFLD having both low muscle volume and high muscle fat (69).”
BackgroundInfluentialMurton, A. J., Marimuthu, K., Mallinson, J. E., Selby, A. L., Smith, K., Rennie, M. J., & Greenhaff, P. L. (2015) · Diabetes · doi:10.2337/db15-0021 · Cited by 97 · cited 1×
“, resistance exercise and essential AAs) are less effective at inducing skeletal muscle protein synthesis in the presence of increased adiposity (102, 103).”
BackgroundReproducibility and repeatability of MRI‐based body composition analysis
Borga, M., Ahlgren, A., Romu, T., Widholm, P., Dahlqvist Leinhard, O., & West, J. (2020) · Magnetic Resonance in Medicine · doi:10.1002/mrm.28360 · Cited by 94 · cited 2×
“(73), would also enable tracking of muscle health, sarcopenic processes, and comorbidities at a much earlier stage and before onset of physical dysfunction.”
BackgroundAbnormal protein turnover and anabolic resistance to exercise in sarcopenic obesity
Nilsson, M. I., Dobson, J. P., Greene, N. P., Wiggs, M. P., Shimkus, K. L., Wudeck, E. V., Davis, A. R., Laureano, M. L., & Fluckey, J. D. (2013) · The FASEB Journal · doi:10.1096/fj.12-224006 · Cited by 87
Peng, T.-C., Wu, L.-W., Chen, W.-L., Liaw, F.-Y., Chang, Y.-W., & Kao, T.-W. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2017.11.021 · Cited by 84
Teigen, L. M., Kuchnia, A. J., Mourtzakis, M., & Earthman, C. P. (2017) · Nutrition in Clinical Practice · doi:10.1177/0884533616676264 · Cited by 75
Koopmans, S. J., Kushwaha, R. S., & DeFronzo, R. A. (1999) · Metabolism · doi:10.1016/s0026-0495(99)90081-1 · Cited by 48
Cited by
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Self-citationA Global View of the Interplay between Non-Alcoholic Fatty Liver Disease and Diabetes
Stefan, N., & Cusi, K. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00003-1 · Cited by 593
Peiseler, M., Schwabe, R., Hampe, J., Kubes, P., Heikenwälder, M., & Tacke, F. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.012 · Cited by 564
Bo, T., Gao, L., Yao, Z., Shao, S., Wang, X., Proud, C. G., & Zhao, J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.04.006 · Cited by 293
Nachit, M., Kwanten, W. J., Thissen, J.-P., Op De Beeck, B., Van Gaal, L., Vonghia, L., Verrijken, A., Driessen, A., Horsmans, Y., Francque, S., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.02.037 · Cited by 114
Metadata
- Authors
- Chakravarthy, M. V., Siddiqui, M. S., Forsgren, M. F., & Sanyal, A. J.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2020-12-23
- Volume
- 11
- Pages
- 592373-592373
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W3116305102
- Cited by
- 88
- References
- 64
- FWCI
- 6.45
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.